ReviewFrontiers in medicine2026
Clinical evidence for low-molecular-weight collagen peptides in tendon and ligament tears: a systematic review with narrative synthesis.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Low-molecular-weight hydrolyzed collagen peptides are increasingly used as adjuncts in musculoskeletal medicine, but their clinical role in tendon and ligament injuries remains unclear. Objective: To evaluate clinical evidence on oral or injectable hydrolyzed collagen peptides, or related low-molecular-weight peptide preparations, in tendon and ligament injuries and post-repair/reconstruction settings. Methods: A systematic review with narrative synthesis was conducted using PubMed and a mirrored Scopus strategy through 17 March 2026. Eligible studies were human clinical studies assessing hydrolyzed collagen peptides or clearly related low-molecular-weight peptide formulations in tendon tears, ligament tears, or postoperative repair/reconstruction. Closely related disorders were included only as contextual evidence when direct injury-specific data were limited. Results: Six studies met the eligibility criteria. Three provided direct evidence in tear or post-surgical populations: one pilot study of injectable low-molecular-weight peptides in partial supraspinatus tendon tears, one randomized trial after ACL reconstruction, and one randomized trial after rotator cuff repair. Three additional studies provided indirect evidence in Achilles tendinopathy, chronic ankle instability, and rotator cuff tendinopathy. Overall, collagen-based interventions were associated with improvements in pain, function, analgesic use, or imaging-related outcomes. However, most oral interventions were multicomponent, and only one direct tear study evaluated a clearly defined low-molecular-weight peptide formulation. Conclusions: Hydrolyzed collagen-derived peptides show a cautiously positive signal as adjuncts to rehabilitation or postoperative care. However, evidence in tendon and ligament tears remains sparse, heterogeneous, and low certainty. Further blinded, placebo-controlled trials using well-characterized formulations and clinically meaningful outcomes are needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.